Mike Ryan (ex-Harvard Endowment) on the mistake that keeps smart investors at index returns

Mike Ryan (ex-Harvard Endowment) on the mistake that keeps smart investors at index returns

Mike Ryan is the founder of Bullet Point Network. Before that he spent two decades at Goldman Sachs, where he was a partner and co-head of Global Equities, and then sat on the investment committee at the Harvard Endowment, allocating $ 12B to outside funds and $ 6B directly into companies.


The episode opens with a comparison the host can't reconcile: one of the best-known venture firms published its performance, and measured against a Nasdaq-100 index fund the average return came out slightly below the index — with much worse liquidity. That pattern isn't unique to one firm. So how do a hundred very smart analysts produce index-matching returns?


Ryan's answer has two parts. The first is that public technology stocks have had an unusually strong run on a risk-adjusted basis over the last five, ten and seventeen years. The second is about what goes wrong inside investment firms, and it isn't what most people assume: the largest funds see nearly every deal, employ excellent people, and produce enormous amounts of analysis. What that analysis often contains, he argues, is a repackaging of information the company itself supplied. A firm can hire very smart people, build a beautiful process, and still deliver index-like returns or worse.


He then pushes back on the premise. The last five years had a specific problem — funds haven't been able to exit and realise profits — and meanwhile the value creation has moved into private markets. Companies are now going from nothing to a hundred billion, and in a few cases close to a trillion, before they ever go public. He points out that Microsoft, one of the best companies of its era, did almost all of its growing as a public company, and says the new pattern is something he has not seen before in his lifetime.


The host raises Ryan's undergraduate thesis, written at Yale under David Swensen, who created the endowment model that pushed universities toward illiquid assets, and asks whether he ever suspected the model had stopped fitting. Ryan treats the 2008 financial crisis as the real test of that conviction: institutions forced to sell into the liquidity crunch suffered badly, while those who held were rewarded over the following two decades. But he expects the next ten to twenty years to be weaker than the last, largely because interest rates are returning to normal levels, and he grants directly that venture returns over the past decade have not objectively beaten the Nasdaq. The first segment ends on what actually lets an investor hold through a downturn: the temperament to stay invested, and a structure with no capital calls to meet.


From there the conversation moves to where fund size and fee income pull a manager's incentives away from the people whose money they manage, and why the current buildout may nonetheless require very large funds. Ryan is asked whether making a firm more rigorous can make it worse — whether a fund can pressure-test its way out of the one bet that would have returned it — and where he draws the line between the work he hands to AI systems and the work he insists a human keep. The last third turns to the audience's own problem: how a founder with no revenue and no product should present a real probability of failure to an investor, and what the best of them have stopped hiding.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(22)

From Code to Cures: Mark DePristo on the Zero-to-One Biotech Journey

From Code to Cures: Mark DePristo on the Zero-to-One Biotech Journey

Mark DePristo, former CEO of BigHat Biosciences, reveals why the best biotech innovation doesn't bolt on AI later but bakes it into research from day one. He shifts from scaling a clinical-stage antib...

8 Heinä 38min

Automating Scientific Discovery with MIT Professor Markus J. Buehler

Automating Scientific Discovery with MIT Professor Markus J. Buehler

In this episode of the Machines and Molecules podcast, host Marcus Bühler, the McAfee Professor of Engineering at MIT, discusses the principle of "adaptability" as the most important universal princip...

26 Helmi 43min

Chris Bahl on the Conundrum of Biotech Platforms

Chris Bahl on the Conundrum of Biotech Platforms

Chris Bahl is founder and CEO of AI Proteins. The conversation delves into the challenges faced by platform companies in the biotech sector, highlighting the financial pressures that lead to the cutti...

21 Marras 202533min

Pioneering Molecular Modeling: Victor Guallar’s Insights on Monte Carlo, AI, and Biophysics

Pioneering Molecular Modeling: Victor Guallar’s Insights on Monte Carlo, AI, and Biophysics

Victor Guallar is an ICREA Professor and group leader of the EAPM at the Barcelona Supercomputing Center and Co-Founder of Nostrum Biodiscovery. With a joint PhD from the Autonomous University of Barc...

11 Joulu 202432min

Building Bridges in Biotech: Markus Müller on CLIB’s Role in Creating a Collaborative and Connected Bioeconomy

Building Bridges in Biotech: Markus Müller on CLIB’s Role in Creating a Collaborative and Connected Bioeconomy

Markus Müller is an experienced project manager with expertise in biotechnology and bioeconomy, focused on bridging research and industry to advance sustainable bioprocesses. As Project Manager at CLI...

5 Marras 202435min

Accelerating AI Innovation: Laura Möller’s Mission to Shape the Startup Ecosystem and Foster Entrepreneurship in Academia.

Accelerating AI Innovation: Laura Möller’s Mission to Shape the Startup Ecosystem and Foster Entrepreneurship in Academia.

Laura Möller is a seasoned expert in venture capital and entrepreneurship, with a focus on artificial intelligence and technology transfer. She holds leadership roles as Director of the Künstliche Int...

10 Loka 202433min

Productizing Research Code: Martin Steinegger on how to create useful and reusable Software

Productizing Research Code: Martin Steinegger on how to create useful and reusable Software

Dr. Martin Steinegger is an expert in computational biology and bioinformatics, specializing in large-scale sequence data analysis. He earned his Ph.D. from the Technical University of Munich in colla...

6 Syys 202433min

Suosittua kategoriassa Tiede

tiedekulma-podcast
utelias-mieli
rss-mita-tulisi-tietaa
rss-duodecim-lehti
rss-hereilla
docemilia
rss-kasvikutsut
rss-vaasan-yliopiston-podcastit
rss-radplus